Metrics as of 10/16/2026, 11:46 PM (Berlin time), refresh in progress.
Immatics Stock
Immatics N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- CEO
- Harpreet Singh
- Employees
- 704
- Market cap
- $1 B
- IPO
- 12/12/2018
Immatics N.V. (IMTX) operates in the healthcare/biotechnology sector and specializes in developing T-cell receptor-based immunotherapies to combat cancer. The company's research focus is primarily on solid tumors, pursuing two distinct strategies: adoptive cell therapy (ACT) and antibody-like TCR bispecifics. Its…
AI-generated company profile based on the figures on this page, last updated on 04/08/2026. Not investment advice.
Immatics stock: price history
1D
-5.7%
1W
-9.4%
1M
-22.1%
6M
-39.7%
YTD
-35.9%
1Y
-34.0%
2Y
-28.8%
5Y
-51.4%
10Y
–
Next earnings date
Next earnings date
17/11/2026 (in 31 days)
Volatility around earnings
~12% stronger price swings than usual
Immatics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 27/08/2026.
Ask the agents about Immatics
Analyst assessment of Immatics
PRICE TARGET LOW
US$15.00
CONSENSUS
US$16.00
MEDIAN
US$16.00
PRICE TARGET HIGH
US$17.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 19/05/2026
Immatics stock metrics
P/E
-3.76
P/B
2.05
EV/EBITDA
-3.5
RETURN ON EQUITY
-15.6%
NET MARGIN
-683.4%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.4%
FLOAT SHARES
127,716,122
AVG. DAILY VOLUME (30D)
859,800
Insider transactions (SEC)
PERCEPTIVE ADVISORS LLC
Attention
Price since yesterday: -5.7%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Immatics stock
What does Immatics do?
Immatics N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Germany.
The CEO is Harpreet Singh, the company employs around 704 people.
The IPO was on 12/12/2018; the stock trades on NASDAQ under the ticker IMTX.
What do analysts say about Immatics stock?
8 analysts rate the stock, the consensus is Buy (as of 19/05/2026).
The average price target is US$16.00, ranging from US$15.00 to US$17.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
When does Immatics report next?
The next earnings date is 17/11/2026.
Around past earnings, price swings were roughly 12% stronger than usual.
Does Immatics pay a dividend?
No, Immatics currently does not pay a dividend.
Which stocks are comparable to Immatics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Immatics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immatics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.